Bio-techne is a Top S&P 500 Stock. Germany's Merck is Paying a 24% Premium for the Company.

Dow Jones

06/26

Shares of Bio-Techne surged Thursday after Germany's Merck KGaA announced it agreed to purchase the company for $11.3 billion.

Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the S&P 500 for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data.

Merck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock's closing price from Wednesday. The deal is expected to close later this year or early in 2027.

Merck said the acquisition of Bio-Techne will strengthen its presence in the life sciences market. Bio-Techne provides analytical technologies and life science tools used by researchers and drug manufacturers.

"Building on our strong track record in the life science business, this transaction strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences," said Jean-Charles Wirth, a member of the executive board of Merck KGaA, in the media release.

Write to Kit Norton at kit.norton@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

June 25, 2026 15:12 ET (19:12 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2646025388"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2646025388\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2646025388?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 03:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646025388","market":"sg","top_or_hot":-1,"title":"Bio-techne is a Top S&P 500 Stock. Germany's Merck is Paying a 24% Premium for the Company.","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Shares of Bio-Techne surged Thursday after Germany's <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a> announced it agreed to purchase the company for $11.3 billion. \n</p>\n<p>\n  Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the S&amp;P 500 for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a> plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock's closing price from Wednesday. The deal is expected to close later this year or early in 2027. \n</p>\n<p>\n  Merck said the acquisition of Bio-Techne will strengthen its presence in the life sciences market. Bio-Techne provides analytical technologies and life science tools used by researchers and drug manufacturers. \n</p>\n<p>\n  \"Building on our strong track record in the life science business, this transaction strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences,\" said Jean-Charles Wirth, a member of the executive board of Merck KGaA, in the media release. \n</p>\n<p>\n  Write to Kit Norton at kit.norton@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 25, 2026 15:12 ET (19:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-techne is a Top S&P 500 Stock. Germany's Merck is Paying a 24% Premium for the Company.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-techne is a Top S&P 500 Stock. Germany's Merck is Paying a 24% Premium for the Company.\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-06-26 03:12</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Shares of Bio-Techne surged Thursday after Germany's <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a> announced it agreed to purchase the company for $11.3 billion. \n</p>\n<p>\n  Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the S&amp;P 500 for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a> plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock's closing price from Wednesday. The deal is expected to close later this year or early in 2027. \n</p>\n<p>\n  Merck said the acquisition of Bio-Techne will strengthen its presence in the life sciences market. Bio-Techne provides analytical technologies and life science tools used by researchers and drug manufacturers. \n</p>\n<p>\n  \"Building on our strong track record in the life science business, this transaction strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences,\" said Jean-Charles Wirth, a member of the executive board of Merck KGaA, in the media release. \n</p>\n<p>\n  Write to Kit Norton at kit.norton@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 25, 2026 15:12 ET (19:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2646025388","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646025388","pubTimestamp":1782414720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Bio-Techne surged Thursday after Germany's Merck KGaA announced it agreed to purchase the company for $11.3 billion.Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","MKKGY":"Merck KGaA","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","TECH":"Bio-Techne","BK4585":"ETF&股票定投概念","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","BK4588":"碎股","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","BK4121":"生命科学工具和服务"},"translate_title":"Bio-techne是标普500的顶级股票。德国默克公司为该公司支付了24%的溢价。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":1.97,"MKKGY":1.91},"content_text":"Shares of Bio-Techne surged Thursday after Germany's Merck KGaA announced it agreed to purchase the company for $11.3 billion. \n\n\n  Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the S&P 500 for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data. \n\n\nMerck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock's closing price from Wednesday. The deal is expected to close later this year or early in 2027. \n\n\n  Merck said the acquisition of Bio-Techne will strengthen its presence in the life sciences market. Bio-Techne provides analytical technologies and life science tools used by researchers and drug manufacturers. \n\n\n  \"Building on our strong track record in the life science business, this transaction strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences,\" said Jean-Charles Wirth, a member of the executive board of Merck KGaA, in the media release. \n\n\n  Write to Kit Norton at kit.norton@barrons.com \n\n\n   This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 25, 2026 15:12 ET (19:12 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}